Polaryx Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance
Polaryx Therapeutics, Inc. (PLYX) had Deferred Tax Assets, Valuation Allowance of $6.39 million as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-24
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $6.39M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $4.87M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $6.39M 10-K · filed 2026-03-24 |
| 2024-12-31 | $4.87M 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |